Longeveron Inc (LGVN) Stock Price, Quote & News

Company Profile

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to...

Industry: Biotechnology

Sector: Healthcare

Phone: 844 470 2550

Website: longeveron.com

Address:

Life Science & Technology Park, Suite 520 1951 NW 7th Avenue, Miami, United States

DivineCandles Mar. 16 at 12:37 AM

$IPM good start overnight. Lets have a great week! Eye also on : $FMFC $MEHA $LGVN

0 · Reply

KevMomentum Mar. 15 at 11:50 PM

$LGVN - "Longeveron closes USD 15 million private placement of shares" Over 50x relative volume on its initial breakout last week over its 200MA, followed by multiple days of low relative vol consolidation... now, I'll be looking for continuation on the break over daily highs. As always, no break means no trade. Range to $1.4/$1.6 on the break

0 · Reply

DayTrade_4Life Mar. 15 at 8:21 PM

👀Some Stocks to Watch for Monday 16 March: $CLIK $AIFF $BIAF $EONR $LGVN TURB SVCO 🏆TOP ALERTS SO FAR IN MARCH 2026 IN IMAGE. 💰See Pinned Post to JOIN US & learn how to get profits 🔥Join me on X. Link in Profile.

0 · Reply

DwigtMcDichael Mar. 15 at 4:18 PM

$LGVN Sucks that had to give up full voucher proceeds. Guess they’re desperate enough to bet on their future. ^ + TA is why im in

0 · Reply

DayTrade_4Life Mar. 15 at 3:18 PM

$CLIK Click Holdings Limited (NASDAQ: CLIK) Reports Strong Growth in Silver Economy Segment, with 100% Increase in Service Hours and 34% Rise in CCSV Cases 💵Latest Market News and Parabolic Scanner Alerts Check Us Out. Live Alerts, Swings & Education too. $ONDS $IBRX $AIFF $LGVN

0 · Reply

Drerekcohert90 Mar. 15 at 2:37 PM

$LGVN Nice call last week @jacksparo worth every penny to join your groups!

0 · Reply

conclusionsq Mar. 15 at 11:29 AM

$ACXP since i posted, this went up +200%, and then i sold all of my stock. Next target is $LGVN

0 · Reply

conclusionsq Mar. 15 at 6:42 AM

$LGVN intersting. next week $9+

1 · Reply

BottomzUp Mar. 14 at 6:20 PM

$LGVN 2+ next week is very plausible

0 · Reply

StockScanners Mar. 14 at 5:43 PM

$LGVN keep watch if this holds above .95

0 · Reply

Longeveron Announces Closing of Private Placement of up to $30 Million

Mar 10, 2026, 3:58 PM EDT - 5 days ago

Longeveron (LGVN) Shares Surge On $30 Million Private Placement Deal

Feb 25, 2026, 11:05 AM EST - 18 days ago

Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell

Feb 13, 2026, 4:30 PM EST - 4 weeks ago

Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

Feb 5, 2026, 9:15 AM EST - 5 weeks ago

Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program

Jan 29, 2026, 9:15 AM EST - 6 weeks ago

Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

Dec 29, 2025, 9:15 AM EST - 2 months ago

Longeveron, Selected as a StartUp Health Alzheimer's Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026

Dec 2, 2025, 9:15 AM EST - 3 months ago

Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging

Dec 1, 2025, 12:00 PM EST - 3 months ago

Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer's Disease Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)

Nov 19, 2025, 9:15 AM EST - 4 months ago

Longeveron Laromestrocel Data in Alzheimer's Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)

Nov 12, 2025, 9:05 AM EST - 4 months ago

Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy

Nov 4, 2025, 9:36 PM EST - 4 months ago

Longeveron Inc. (LGVN) Q3 2025 Earnings Call Transcript

Oct 27, 2025, 9:15 AM EDT - 4 months ago

Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect

Oct 6, 2025, 9:15 AM EDT - 5 months ago

Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Sep 22, 2025, 9:15 AM EDT - 6 months ago

Longeveron® to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Sep 3, 2025, 4:05 PM EDT - 6 months ago

Longeveron® Announces Key Leadership Updates

Aug 20, 2025, 9:15 AM EDT - 7 months ago

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 13, 2025, 10:55 PM EDT - 7 months ago

Longeveron Inc. (LGVN) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 4:05 PM EDT - 7 months ago

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 11, 2025, 4:15 PM EDT - 7 months ago

Longeveron Announces Closing Of Up To $17.5 Million Public Offering

Aug 8, 2025, 1:28 PM EDT - 7 months ago

Longeveron Announces Up To $17.5 Million Public Offering

Aug 5, 2025, 9:15 AM EDT - 7 months ago

Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

Jul 21, 2025, 9:15 AM EDT - 8 months ago

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

Jul 8, 2025, 9:15 AM EDT - 8 months ago

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

Jun 26, 2025, 9:05 AM EDT - 9 months ago

Longeveron® Appoints Than Powell as Chief Business Officer

Jun 24, 2025, 6:30 AM EDT - 9 months ago

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Jun 9, 2025, 9:15 AM EDT - 9 months ago

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

May 20, 2025, 9:15 AM EDT - 10 months ago

Longeveron® to Attend BIO International Convention 2025

May 12, 2025, 7:15 AM EDT - 10 months ago

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

May 9, 2025, 5:31 PM EDT - 11 months ago

Longeveron Inc. (LGVN) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 11 months ago

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

May 2, 2025, 8:30 AM EDT - 11 months ago

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease

Mar 5, 2025, 9:25 AM EST - 1 year ago

Longeveron® to Present at the 37th Annual Roth Conference

Feb 28, 2025, 7:04 PM EST - 1 year ago

Longeveron Inc. (LGVN) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 4:04 PM EST - 1 year ago

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

Feb 18, 2025, 9:25 AM EST - 1 year ago

Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

Dec 18, 2024, 9:10 AM EST - 1 year ago

Longeveron to Present at Biotech Showcase 2025

Dec 2, 2024, 9:05 AM EST - 1 year ago

Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024

Nov 12, 2024, 10:37 PM EST - 1 year ago

Longeveron, Inc. (LGVN) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 9:05 AM EST - 1 year ago

Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

Nov 4, 2024, 4:05 PM EST - 1 year ago

Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Oct 29, 2024, 10:00 AM EDT - 1 year ago

Longeveron® Presents Lomecel-B™ Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Oct 27, 2024, 3:10 PM EDT - 1 year ago

Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Oct 14, 2024, 9:05 AM EDT - 1 year ago

Longeveron® Lomecel-B™ Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Oct 9, 2024, 9:05 AM EDT - 1 year ago

Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Oct 7, 2024, 9:05 AM EDT - 1 year ago

Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day

Oct 2, 2024, 9:05 AM EDT - 1 year ago

Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Sep 26, 2024, 9:05 AM EDT - 1 year ago

Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Aug 26, 2024, 4:05 PM EDT - 1 year ago

Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference

DivineCandles Mar. 16 at 12:37 AM

$IPM good start overnight. Lets have a great week! Eye also on : $FMFC $MEHA $LGVN

0 · Reply

KevMomentum Mar. 15 at 11:50 PM

0 · Reply

DayTrade_4Life Mar. 15 at 8:21 PM

0 · Reply

DwigtMcDichael Mar. 15 at 4:18 PM

$LGVN Sucks that had to give up full voucher proceeds. Guess they’re desperate enough to bet on their future. ^ + TA is why im in

0 · Reply

DayTrade_4Life Mar. 15 at 3:18 PM

0 · Reply

Drerekcohert90 Mar. 15 at 2:37 PM

$LGVN Nice call last week @jacksparo worth every penny to join your groups!

0 · Reply

conclusionsq Mar. 15 at 11:29 AM

$ACXP since i posted, this went up +200%, and then i sold all of my stock. Next target is $LGVN

0 · Reply

conclusionsq Mar. 15 at 6:42 AM

$LGVN intersting. next week $9+

1 · Reply

BottomzUp Mar. 14 at 6:20 PM

$LGVN 2+ next week is very plausible

0 · Reply

StockScanners Mar. 14 at 5:43 PM

$LGVN keep watch if this holds above .95

0 · Reply

minnguy64 Mar. 14 at 12:31 PM

$LGVN great chance to gap up on Monday. We have got to keep it there because shorts have piled in and will try to keep this under 1.00. Has a good chance to keep running. Monday will be a big day here to see who wins!

0 · Reply

Dorps332 Mar. 14 at 11:51 AM

$LGVN needs to start closing above $1 for 10 days to get out of compliance jail and stop the R/S talks that are happening. Hopefully they have something in the earnings that can help this.

0 · Reply

BottomzUp Mar. 14 at 8:55 AM

$LGVN 1.30 - 1.50 on Monday.

0 · Reply

AllinOneinAll Mar. 14 at 12:30 AM

$LGVN break 1.10-20 hold and we talk

0 · Reply

CoreyJ2087 Mar. 13 at 9:09 PM

$LGVN I’m up 91% on commons.

0 · Reply

MisterXa Mar. 13 at 8:34 PM

$LGVN Sad the ABCD setup failed intraday but its still primed for monday morning. Shorts are still pilling up in the 1.00-1.10 area, I expect a squeeze once we break out over that range.

1 · Reply

topstockalerts Mar. 13 at 8:07 PM

$LGVN what a day 🙌

0 · Reply

minnguy64 Mar. 13 at 8:04 PM

$LGVN -- people are getting back in. Looks like it is in play again!

0 · Reply

SunsPHX43 Mar. 13 at 7:58 PM

$LGVN Strong close

0 · Reply

topstockalerts Mar. 13 at 7:56 PM

Top Gainers PT2 $ELPW $ISPC $VACHU $LGVN $MASK

0 · Reply

Shodan84 Mar. 13 at 7:51 PM

$LGVN Our diamond is slowly maturing :)

0 · Reply

BottomzUp Mar. 13 at 7:37 PM

$LGVN lets go apes

0 · Reply

Market Cap	20.77M
Revenue (ttm)	2.39M
Net Income (ttm)	-15.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-668.20%
Debt to Equity Ratio	0.00

Volume	13,548,500
Avg Vol	5,860,052
Day's Range	N/A - N/A
Shares Out	21.33M
Stochastic %K	72%
Beta	0.23
Analysts	Strong Sell
Price Target	$6.86